{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:02:50Z","timestamp":1671606170216},"reference-count":21,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J Cancer Care"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1111\/ecc.13565","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T06:13:27Z","timestamp":1648534407000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implications of systemic adjuvant melanoma treatments for U.K. melanoma services: Results of the U.K. Melanoma Adjuvant Pathway Survey"],"prefix":"10.1155","volume":"31","author":[{"given":"Oliver","family":"Cassell","sequence":"first","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Harwood","sequence":"additional","affiliation":[{"name":"Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London; Barts Health NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Hovey","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Department of Health. (2012).Governance arrangements for research ethics committees: A harmonised edition.https:\/\/www.gov.uk\/government\/publications\/health-research-ethics-committees-governance-arrangements"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6513-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.006"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200241"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00141-8"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx176"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09883.x"},{"key":"e_1_2_9_13_1","unstructured":"Melanoma Focus. (2019).The current role of sentinel lymph node biopsy in the management of cutaneous melanoma\u2014a UK consensus statement based on a multi\u2010disciplinary meeting held in Cambridge UK on 17 May 2018.https:\/\/melanomafocus.com\/wp-content\/uploads\/2019\/01\/SNB-Consensus-Final-1.pdf"},{"key":"e_1_2_9_14_1","first-page":"CD008955","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","volume":"6","author":"Mocellin S.","year":"2013","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"e_1_2_9_15_1","unstructured":"NICE. (2015).Melanoma: Assessment and management. NICE guideline [NG14].https:\/\/www.nice.org.uk\/guidance\/ng14"},{"key":"e_1_2_9_16_1","unstructured":"NICE. (2018a).Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation\u2010positive melanoma. Technology appraisal guidance [TA544].https:\/\/www.nice.org.uk\/guidance\/ta544\/chapter\/1-Recommendations"},{"key":"e_1_2_9_17_1","unstructured":"NICE. (2018b).Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease: final appraisal document.https:\/\/www.nice.org.uk\/guidance\/gid-ta10286\/documents\/final-appraisal-determination-document"},{"key":"e_1_2_9_18_1","unstructured":"NICE. (2018c).Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence: Final appraisal document.https:\/\/www.nice.org.uk\/guidance\/gid-ta10247\/documents\/html-content-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6760"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ecc.13565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ecc.13565","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ecc.13565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:11:06Z","timestamp":1671541866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.13565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/ecc.13565"],"URL":"https:\/\/doi.org\/10.1111\/ecc.13565","archive":["Portico"],"relation":{},"ISSN":["0961-5423","1365-2354"],"issn-type":[{"value":"0961-5423","type":"print"},{"value":"1365-2354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"2019-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}